Kan kültüründen izole edilen Brucella melitensis suşlarına tigesiklinin in-vitro etkinliği

Bruselloz kronik seyirli zoonotik bir hastalıktır. Türkiye’nin özellikle Doğu ve Güneydoğu Anadolu yörelerinde oldukça yaygın rastlanan bu hastalıkta tedavideki yetersizlikler, nüksler ve kullanılan antibiyotiklere ait yan etkilerden dolayı yeni tedavi protokolleri araştırılmaktadır. Bu çalışmada tigesiklinin Brucella bakterilerine in-vitro etkinliğinin araştırılması amaçlanmıştır. Kan kültürü örneklerinden Ocak-Ekim 2006 arasında 10 ayda 39 Brucella spp. suşu izole edilmiştir. Soyutlanan suşların tümü Brucella melitensis olarak tanımlanmıştır. Bu izolatlara tigesiklinin etkinliği E test (AB Biodisk) stripleri kullanılarak test edilmiştir. Çalışmaya alınan suşların MİK değerleri

Anahtar Kelimeler:

Anti-bakteriyel ajanlar, Brucella melitensis, Minosiklin, In vitro, Kültür ortamı, Kan

In-vitro activities of tigecycline for Brucella melitensis strains isolated from blood cultures

Brucellosis is a chronic zoonotic disease. This infection is common mainly in the East and Southeast Turkey. Because the current treatment has disadvantages such as relapse and side effects, new treatment protocols are under investigation. The aim of this study is to evaluate in-vitro activities of tigecycline against Brucella melitensis strains. All of 39 strains isolated in 10 months (January-October 2006) from blood cultures were identified as Brucella melitensis. Tigecycline activity against these isolates was tested by E test (AB Biodisk) strips. The MICs values for 39 blood isolates of B.melitensis were found as <0.016-0.094 µg/ml. It was determined that all isolates in this study have very low MIC values. Based on these findings it seems that tigecycline, efficiently used for several bacterial infections, could also be used for brucellosis treatment and this probability should be investigated by clinical trials.

Keywords:

Anti-Bacterial Agents, Brucella melitensis, Minocycline, In Vitro, Culture Media, Blood,

PDF

___

Akova M, Uzun O, Akalın HE, Hayran M, Ünal S, Gur D: Quinolones in the treatment of human brucellosis: comperative trial of ofloxacin-rifampin versus doxycycline-rifampicin, Antimicrob Agents Chemother 1993;37(9):1831-4.
Ariza J, Guidol F, Pallares R, Rufi G, Fernandez-Viladrich P: Comparative trial of rifampicin-doxycyclin versus tetracycline-streptomycin in therapy of human brucellosis, Antimicrob Agents Chemother 1985;28(4):548-51.
Aygen B, Sümerkan B, Kardaş Y, Doğanay M, İnan M: Bruselloz: 183 olgunun değerlendirilmesi, Klimik Derg 1995;8(1):13-6.
Baysal B: Brusella, "Ustaçelebi Ş, Mutlu G, İmir T, Cengiz AT, Tümbay E, Mete Ö (eds): Temel ve Klinik Mikrobiyoloji" kitabında s. 571-7, Güneş Kitapevi, Ankara (1999).
Bonnetblanc JM: Doxycycline, Ann Dermatol Venereol 2002;129(6-7):874-82.
Chopra I: Glycylcyclines: third-generation tetracycline antibiotics, Curr Opin Pharmacol 2001;1(5):464-9.
Cunha BA: Antibiotic side effects, Med Clin North Am 2001;85(l):149-85.
Domingo S, Gastearena I, Vitas AL et al: Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice, J Antimicrob Chemother 1995;36(4):647-56.
Doyle TJ, Bryan RT: Infectious disease morbidity in US region bordering Mexico, 1990-1998, J Infect Dis 2000;182(5):1503-10.
Geyik MF, Kökoğlu ÖF, Hoşoğlu S, Ayaz C: Brusellozlu 154 hastanın değerlendirilmesi, Dicle Tıp Fak Derg 2002;29(1):1-2.
Livermore DM: Tigecycline: what is it, and where should it be used?, J Antimicrob Chemother 2005;56(4):611-4.
Maletskaia OV: Efficacy of some new antibiotics in treating experimental brucellosis, Antibiot Khimioter 2002;47(11):13-7.
Memish ZA, Balkhy HH: Brucellosis and internal travel,J Travel Med 2004;11(1):49-55.
Montero MJ, Alberola I, Glez-Zarate P et al: Open, randomized therapeutic trial of six antimicrobial agents in the treatment of human brucellosis, Clin Infect Dis 1993;16(5):671-6.
Murray J, Wilson S, Klein S, Yellin A, Loh E: The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trail, 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago (2003).
Pappas G, Akritidis N, Bosilkovski M, Tsianos E: Brucellosis, N Engl J Med 2005;352(22):2325-36.
Pappas G, Papadimimitriou P, Christou L, Akritidis N: Future trends in human brucellosis treatment, Expert Opin Investig Drugs 2006;15(10):1141-9.
Pappas G, Solera J, Akritidis N, Tsianos E: New approaches to the antibiotic treatment of brucellosis, Int J Antimicrob Agents 2005;26(2):101-5.
Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E, Tigecycline 200 Study Group: Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients, Clin Ther 2004;26(5):704-14.
Sümerkan B: Brucella türleri, "Wilke Topçu A, Söyletir G, Doğanay M (eds): İnfeksiyon Hastalıkları ve Mikrobiyoloji" kitabında s.1647-52, Nobel Tıp Kitapevi, İstanbul (2002).
Taşova Y, Saltoğlu N, Şahin G, Aksu HS: Osteoarthricular involvement of brucellosis in Turkey, Clin Rheumatol 1999;18(3):214-9.
Ulusoy S: Tigesiklin, ANKEM Perg 2006;20(Ek 2):117-9. 17.
Westphal JF, Vetter D, Brogard JM: Hepatic side-effectsof antibiotics, J Antimicrob Chemother 1994;33(3):387-401.
World Health Organization: Joint FAO/WHO Expert Committee on Brucellosis. Sixth report, Technical Report Series 740, WHO, Geneva (1986).
Young EJ: Brucella species, "Mandell G, Bennett JI, Dolin R (eds): Principles and Practice Infectious Diseases, 5,baskı" kitabında s.2386-93, Churchill Livingstone, Philadelphia (2000).